Glutamate for Metabolic Intervention in Coronary Surgery II

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

November 15, 2015

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Coronary Artery Bypass SurgeryPostoperative ComplicationsHeart Failure
Interventions
DRUG

glutamate infusion

Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.

DRUG

saline infusion

Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.

Trial Locations (4)

SE41345

Sahlgrenska University Hospital, Gothenburg

SE58185

University Hospital Linköping, Linköping

SE 70185

University Hospital Örebro, Örebro

SE90185

University Hospital Umeå, Umeå

All Listed Sponsors
collaborator

Region Örebro County

OTHER

collaborator

University Hospital, Umeå

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

lead

University Hospital, Linkoeping

OTHER

NCT02592824 - Glutamate for Metabolic Intervention in Coronary Surgery II | Biotech Hunter | Biotech Hunter